Roche enters $1.1B deal with Aileron on up to five undisclosed targets in oncology, virology, inflammation, metabolism and central nervous system
Gilead Science and CGI announce the signing of a Definitive Agreement whereby Gilead will acquire CGI.
R&D Spotlight describes Stapeled Peptides as a revolutionary new class fo drugs to address thousands of currently undruggable targets.
Remember the old "suggestion box" that hit up workers or customers for new ideas? That concept has matured in the 21st century. It's now known as crowdsourcing.
HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing compounds to treat sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of a $12M Series B financing led by new investor, Aberdare Ventures.
GlobeImmune Inc. announced Phase 2b data for GI-5005, the Company’s investigational Tarmogen® product for hepatitis C virus (HCV) infection, correlating GI-5005 treatment response rate and IL-28 B genotype in patients with chronic HCV infection.
Early data show strong correlation between florbetapir PET imaging and Alzheimer’s disease beta-amyloid pathology
Viamet Pharmaceuticals, Inc., a pharmaceutical company developing novel, best in class metalloenzyme inhibitors, announced today that William Moore, Ph.D. has joined the company as Chief Scientific Officer.
Silence Therapeutics plc (“the Company”) (AIM: SLN) and Intradigm Corporation announce that the companies have completed their merger to form a leading company in the field of RNAi (RNA interference).
HemaQuest Pharmaceuticals presented data from new preclinical studies and early results from clinical trials of its lead drug candidate, HQK-1001, in sickle cell disease and beta thalassemia at the annual meeting of the American Society of Hematology in New Orleans.
